ArticleScientific reports2026
A machine learning-based framework for predicting hypertension using serum hematological factors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) is a leading global cause of cardiovascular disease (CVD) and all-cause mortality, underscoring the need for early detection and intervention. This study aimed to develop a machine learning (ML)-based predictive framework for HTN using routinely available hematologic and clinical parameters. We analyzed data from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study (2010-2020). From an initial 9,704 participants, 4,923 individuals (3,033 without and 1,890 with incident HTN) were included after applying predefined inclusion/exclusion criteria and preprocessing. Predictors included hematologic biomarkers (WBC, RBC, MCV, PLT, RDW, PDW, NLR) and clinical/demographic variables (age, sex, smoking, BMI, GFR, physical activity). Missing values (< 10% for most variables) were addressed via median imputation for continuous features. We employed multiple ML algorithms (XGBoost, LightGBM, logistic regression, decision trees, random forests, gradient boosting, k-nearest neighbors, naive Bayes, ExtraTrees, AdaBoost) to develop and compare models. Following model training and performance-based ranking, XGBoost emerged as the top-performing classifier, achieving a ROC-AUC of 0.66 (95% CI: 0.63-0.69). Feature importance analysis identified age, BMI, RBC count, and MCV as the most influential predictors, with consistent rankings across other models. All models exhibited stable performance across training and test sets, indicating minimal overfitting. Our findings demonstrate an ML-driven framework exploring potential signals in HTN risk using routinely available clinical and hematologic data. While the predictive performance reflects the inherent challenge of forecasting a multifactorial disease from baseline variables, this work establishes a transparent, interpretable exploratory benchmark and identifies key modifiable predictors for future validation and enhancement in more comprehensive datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.